Foreword
Richard L Lindstrom is the Founder and Attending Surgeon of Minnesota Eye Consultants and Adjunct Professor Emeritus at the University of Minnesota. He is a board-certified ophthalmologist and internationally recognized leader in corneal, cataract, refractive, and laser surgery. He has been at the forefront of ophthalmology’s evolutionary changes throughout his career, as a recognized researcher, teacher, inventor, writer, lecturer and highly acclaimed physician and surgeon.
Author bold biography
A
major trend worldwide is the progressive aging of the population. It is estimated that in the US, patients over 65 years of age consume 10 times the eye care of those under 65 years of age. Thus, ophthalmologists can expect an ever-expanding group of patients with age-related eye disease, including corneal pathology such as Fuchs’ dystrophy, ocular surface disease including trachoma in the developed world, cataract, glaucoma, diabetic retinopathy, and age-related macular degeneration (ARMD).
An important change in the field of corneal surgery is the trend toward anterior and posterior lamellar transplants in place of penetrating keratoplasty. Leading the transition are the multiple forms of endothelial keratoplasty for the treatment of Fuchs’ dystrophy and aphakic and pseudophakic bullous keratopathy. This lamellar surgery is much less invasive with a lower incidence of sight-threatening complications and a lower morbidity, with more rapid visual recovery. The trend is toward ever-thinner posterior lamellar transplants and it can be anticipated that transplantation of Descemet’s membrane alone, with its attached endothelial cell layer, will soon dominate; perhaps in the future endothelial transplantation alone will become a reality.
In developing countries, trachoma with secondary trichiasis continues as a major cause of corneal blindness, and the resulting scarred and vascularized cornea responds poorly to penetrating keratoplasty, which in any case is rarely available. Prevention of this devastating cause of blindness is best accomplished with a combination of patient education, medical therapy, and lid surgery for secondary trichiasis before the cornea is irreversibly damaged.
Cataract surgery also continues to evolve, and again the theme is toward minimally invasive micro-incision surgery to progressively enhance safety and efficacy. Today, cataracts can be safely removed and replaced with an intraocular lens through incisions between 1 and 2mm. Coaxial and biaxial approaches are available for microincision phacoemulsification, with coaxial surgery domination in the US and biaxial in Europe. In addition, in the developing world, sutureless, small-incision, extra-capsular cataract extraction combined with intraocular lens implantation is gaining traction as the preferred approach. A low-cost multifocal intraocular lens would be a great benefit to the patient where access to spectacles is a rare luxury. For the glaucoma patient it is interesting that cataract surgery is also highly beneficial in lowering intraocular pressure (IOP). In the patient with a pressure of 25mmHg after medication washout, an IOP reduction of 6mmHg or more can be anticipated; this is a great advance in our knowledge. In addition, the not uncommon bleb failures following filtering surgery can be reduced with antimetabolites and treated with needling in the office. Many new minimally invasive alternatives to the classic trabeculectomy are advancing through early-stage development and are being adopted into clinical practice. The future promises genetic-based approaches to diagnosis, prognosis, counseling, and, eventually, treatment.
The advances in the diagnosis and treatment of age-related retinal disease are remarkable. Who among us could have predicted a decade ago that we would have an effective therapy for exudative ARMD? The primary age-related retinal causes of blindness in advanced countries remain ARMD, diabetic retinopathy, and vascular occlusion. In each of these, early diagnosis allows therapy that can reduce the risk of vision loss. Appropriate therapy still includes laser photocoagulation, which itself has evolved; however, medical therapy with intra-vitreal steroids and vascular endothelial growth factor inhibitors is playing an increasing role in our therapeutic armamentarium. Genetic testing can be anticipated to allow proactive determination of those at highest risk before disease presents and in the future gene-based therapy will likely dominate.
The following articles are timely and provide valuable information for the practicing ophthalmologist. I trust you will find the diverse content of US Ophthalmic Review a fascinating read. n
© TOUCH BRIEFINGS 2011
11
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116